Folio · SPXSet Report · Digest
v0.7.0 STABLE · 2026-11-11 · r4

2026-W46 · Nov 9–Nov 15 · Company · Profile · published

Index >>> Company >>> Profile

Labcorp Holdings Inc. (LH) — XLV Health Care · S&P 500 Profile |拉伯克介紹

health-careS&P500xlv
SPXSet Studio
IN-HOUSE RESEARCH · 站內獨立研究

Labcorp Holdings Inc. (LH) — Business, History & S&P 500 Profile |拉伯克介紹

Labcorp company profile · diagnostics & biopharma laboratory services · history · financial snapshot · S&P 500 rank #329 · 拉伯克公司業務歷史財務與標普500地位

中文版 ↓

PROFILE
Market data as of Nov 2, 2026 (frozen benchmark)
Financials: FY2025 (ended Dec 31, 2025)
MARKET CAP
$29.16B
Nov 2, 2026 · Slickcharts (frozen benchmark)
S&P 500 WEIGHT
0.04%
Rank #329 · Nov 2, 2026 (Slickcharts)
FY2025 REVENUE
$13.95B
+7.2% YoY
FY2025 NET INCOME
$876.5M
FY2025 net earnings attributable

SNAPSHOT

TickerLH (NYSE)
CompanyLabcorp Holdings Inc.
GICS sector / industryHealth Care (XLV) / Health Care Services
S&P 500 rank (by weight)#329 · 0.04% (Nov 2, 2026)
Sector rank (by market cap)#43 in Health Care (Nov 2, 2026)
Share price (frozen benchmark)$359.07 (Nov 2, 2026)
HeadquartersBurlington, North Carolina
Founded1969 (as National Health Laboratories)
CEOAdam Schechter (Chairman and CEO)
Employeesnearly 71,000 (FY2025)
Market cap$29.16B (Nov 2, 2026)

WHAT IT DOES

Labcorp is one of the world's largest laboratory companies, running diagnostic testing for physicians, hospitals and patients, and biopharma laboratory services for drug developers, through a network of laboratories, patient service centers and a large esoteric testing menu.

The model is volume plus menu: routine tests bring scale, while specialty and genetic tests bring price. FY2025 revenue was $13.95B, up 7.2% from $13.01B, GAAP operating income was $1,384.7M, adjusted operating income was $2,001.6M, net earnings attributable were $876.5M, and diluted EPS was $10.46 (adjusted $16.44).

Diagnostics is the anchor: Diagnostics Laboratories revenue was $10,876.5M, up 7.2%, while Biopharma Laboratory Services revenue of $3,075.5M is derived as total revenue minus Diagnostics, up 7.4% on the same derived basis.

BUSINESS SEGMENTS — FY2025

SegmentRevenueShareYoY
Diagnostics Laboratories$10,876.5M—+7.2%
Biopharma Laboratory Services$3,075.5M (derived)—+7.4% (derived)
Source: Labcorp FY2025 release (Feb 17, 2026). Diagnostics revenue is as reported; Biopharma revenue is derived as total revenue minus Diagnostics, and its YoY is derived the same way — the derivation is stated, not hidden.

HISTORY

YearMilestone
1969National Health Laboratories founded
1995Laboratory Corporation of America formed, combining National Health Laboratories and Roche Biomedical Laboratories
2023Labcorp Holdings spins off Fortrea, its clinical development business
2025FY2025 revenue reaches $13.95B, up 7.2%

COMPETITIVE POSITION

  • Scale — one of two national laboratory networks in the U.S.
  • Esoteric menu — specialty and genetic tests carry higher prices than routine panels.
  • Biopharma services — central laboratory work for drug trials diversifies beyond routine testing.
  • Payer pressure — insurers and Medicare set prices for much of the volume.
  • Competition — the other national laboratory network and hospital in-house laboratories contest the same volumes.

FINANCIAL SNAPSHOT — FY2025

Total revenue$13.95B (+7.2% YoY)
GAAP operating income$1,384.7M
Adjusted operating income (stated separately)$2,001.6M
Net earnings attributable / Diluted EPS$876.5M / $10.46 (adjusted $16.44)
Source: Labcorp FY2025 release (Feb 17, 2026). GAAP and adjusted operating income are stated separately, not mixed. FY2026 figures are not used: Labcorp's fiscal year ends Dec 31, and FY2025 is the latest full year at drafting time.

KEY RISKS

  • Reimbursement — payer fee schedules can cut prices on routine tests.
  • Test volumes — physician visit trends set demand.
  • Biopharma cycles — drug trial spending follows biotech funding.
  • Labor costs — phlebotomists and technologists are hard to staff.
  • Regulation — FDA oversight of laboratory-developed tests can change the menu.

WHY IT MATTERS FOR THE S&P 500

Labcorp is the S&P 500's diagnostics name: at a 0.04% index weight and #43 in Health Care by market cap, it is the index's main exposure to laboratory testing volumes.

Its test volumes are a standing read on U.S. healthcare utilization — requisition counts move before claims data does.

SOURCES & METHODOLOGY

Market dataSlickcharts S&P 500 by weight (rank, weight, price — Nov 2, 2026 close) and Slickcharts S&P 500 analysis page (market cap)
FinancialsLabcorp FY2025 results, release dated Feb 17, 2026 (fiscal year ended Dec 31, 2025), company profile sources
Sector classificationGICS (Health Care Services) via the List of S&P 500 companies (Wikipedia)
Library dataSPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information.

Price Chart — 10-Year Monthly Candles

LH

Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com

FINANCIALS

繁體中文版

公司快照

代碼LH(NYSE)
公司Labcorp Holdings Inc.
GICS 板塊/行業醫療保健(XLV)/醫療保健服務
標普500排名(按權重)#329 · 0.04%(2026 年 11 月 2 日)
板塊內排名(按市值)醫療保健第 #43(2026 年 11 月 2 日)
股價(凍結基準)$359.07(2026 年 11 月 2 日)
總部美國北卡羅來納州伯靈頓
成立1969 年(前身為 National Health Laboratories)
行政總裁Adam Schechter(董事長兼行政總裁)
員工近 71,000(FY2025)
市值$29.16B(2026 年 11 月 2 日)

業務概覽

拉伯克是全球最大的實驗室公司之一,透過實驗室、病人服務中心與大型專科檢測項目,為醫生、醫院與病人提供診斷檢測,並為藥物開發商提供生物製藥實驗室服務。

其模式為銷量加項目:常規檢測帶來規模,專科與基因檢測帶來價格。FY2025 收入為 $13.95B,同比增長 7.2%(FY2024 為 $13.01B),GAAP 營業利潤為 $1,384.7M,經調整營業利潤為 $2,001.6M,歸屬淨利潤為 $876.5M,攤薄每股收益為 $10.46(經調整 $16.44)。

診斷是支柱:診斷實驗室收入為 $10,876.5M,同比增長 7.2%;生物製藥實驗室服務收入 $3,075.5M 為總收入減診斷之推算數,同比按同一推算口徑增長 7.4%。

業務板塊 — FY2025

板塊收入佔比同比
診斷實驗室$10,876.5M—+7.2%
生物製藥實驗室服務$3,075.5M(推算)—+7.4%(推算)
來源:拉伯克 FY2025 公告(2026 年 2 月 17 日)。診斷收入如申報;生物製藥收入為總收入減診斷之推算數,同比按同一口徑推算——推算已明示,並無隱瞞。

歷史沿革

年份里程碑
1969National Health Laboratories 創立
1995Laboratory Corporation of America 成立,合併 National Health Laboratories 與 Roche Biomedical Laboratories
2023Labcorp Holdings 分拆臨床開發業務 Fortrea
2025FY2025 收入達 $13.95B,同比增長 7.2%

競爭地位

  • 規模——美國兩大全國實驗室網絡之一。
  • 專科項目——專科與基因檢測價格高於常規組合。
  • 生物製藥服務——藥物試驗中心實驗室工作分散於常規檢測之外。
  • 付款方壓力——保險商與聯邦醫療保險為大部分銷量定價。
  • 競爭——另一全國實驗室網絡與醫院內部實驗室爭奪同一批銷量。

財務快照 — FY2025

總收入$13.95B(同比 +7.2%)
GAAP 營業利潤$1,384.7M
經調整營業利潤(分開列示)$2,001.6M
歸屬淨利潤/攤薄每股收益$876.5M/$10.46(經調整 $16.44)
來源:拉伯克 FY2025 公告(2026 年 2 月 17 日)。GAAP 與經調整營業利潤分開列示,不相混淆。未用 FY2026 數字:拉伯克財政年度截至 12 月 31 日,起草時 FY2025 為最新完整年度。

主要風險

  • 報銷——付款方收費表可削減常規檢測價格。
  • 檢測銷量——醫生就診趨勢決定需求。
  • 生物製藥週期——藥物試驗開支跟隨生物科技資金。
  • 勞工成本——抽血員與技術員難以招聘。
  • 監管——FDA 對實驗室開發檢測的監管可改變項目。

對標普500的重要性

拉伯克是標普500的診斷標的:指數權重 0.04%、醫療保健板塊市值第 #43,是指數對實驗室檢測銷量的主要敞口。

其檢測銷量,是美國醫療使用量的常設讀數——檢測申請數往往先於理賠數據變動。

來源與方法

市場數據Slickcharts 標普500權重榜(排名、權重、價格——2026 年 11 月 2 日收盤)及 Slickcharts 標普500分析頁(市值)
財務拉伯克 FY2025 業績,2026 年 2 月 17 日公告(財政年度截至 2025 年 12 月 31 日)、公司簡介來源
板塊分類GICS(醫療保健服務),據 S&P 500 公司清單(Wikipedia)
圖庫數據SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。

10年股價K線圖(月K)

LH

來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com

財報

SPXSet Studio

SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。

SPXSet · Company Library · LH
Data as of Nov 2, 2026 · Financials FY2025 (10-K) · Market data Nov 2026
Previous · Dover Corporation (DOV) — XLI Industrials · S&P 500 Profile |多佛介紹Next · ResMed Inc. (RMD) — XLV Health Care · S&P 500 Profile |瑞思邁公司介紹

Entered 2026-11-03 13:04 · updated 2026-11-14 23:44 · rev 6